ASIA PACIFIC ALOPECIA TREATMENT MARKET ANALYSIS

Asia Pacific Alopecia Treatment Market, By Treatment Type (Topical Drugs (Creams, Oils, Gels, Shampoo, Lotions, Foam Oral Drugs, Injectables ( Platelet Rich Plasma, Steroid Injections, Injectable Filler), Hair Transplant Services, Low-Level Laser Therapy), By Disease Indication (Alopecia Areata, Alopecia Totalis, Alopecia Universalis), By End User (Hospitals, Dermatologic and Trichology Clinics, Home care settings, Aesthetic Clinics), and By Country ( China, Japan, Australia, New Zealand, Malaysia, India, Singapore, Vietnam, Philippines, Rest Of APAC)-

Published In : Jul 2023
Code : CMI3958
Pages :160
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Asia Pacific Alopecia Treatment Market: Key Developments

On March 18, 2023, Concert Pharmaceuticals, which was acquired by Sun Pharmaceutical Industries Limited, pharmaceutical company in India, announced that it will report data from its Phase 3 clinical trial THRIVE-AA2. The presentation will highlight the results of the THRIVE-AA2 study, which evaluated the oral investigational drug deruxolitinib in adult patients with moderate to severe alopecia areata.

On June 13, 2022, Eli Lilly and Company and Incyte, Delaware-based drug discovery and development company, announced that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT (baricitinib), a once-daily pill, as the first systemic drug for the treatment of alopecia areata (AA) in adults, available as 4 mg, 2 mg and 1 mg tablets. The recommended dose of OLUMIANT is 2 mg/day, which can be increased to 4 mg/day if the response is inadequate in patients with near-complete or complete scalp alopecia with or without significant hair loss of eyelashes or eyebrows, consider treatment with 4 mg daily.